While it is true that APL M3 is distinct in terms of treatment protocols and prognosis, this subtype shares underlying leukemogenic mechanisms that can intersect with other AML subtypes, particularly in pathways like mTOR signaling. The gene discussed is MTOR; the disease is acute myeloid leukemia.